Presentation is loading. Please wait.

Presentation is loading. Please wait.

BioPlex 2200 HIV Ag-Ab Assay

Published byShanon Bell Modified over 8 years ago

Similar presentations

Presentation on theme: "BioPlex 2200 HIV Ag-Ab Assay"— Presentation transcript:

1 BioPlex 2200 HIV Ag-Ab Assay

2 Introducing the 5th Generation of HIV Diagnostic Testing
Bio-Rad’s BioPlex HIV Ag-Ab assay is the first and only 5th generation fully automated, multiplex flow immunoassay that allows for simultaneous detection, differentiation and reporting of HIV BioPlex® 2200 HIV Ag-Ab Assay

3 HIV Assays 5th Generation 4th Generation Benefits
Detects and Differentiates HIV-1 antibodies (Groups M and O) Detects HIV-2 antibodies Detects Detects and Differentiates HIV-1 p24 antigen Detects Detects and Differentiates BioPlex® 2200 HIV Ag-Ab Assay

4 Overcoming Limitations with Solutions
of 4th Generation Testing Solutions in 5th Generation Testing Result is only Reactive or Non-reactive for an overall result without individual results Automated multiplex flow immunoassay designed to detect, differentiate and report separate values Primary infection samples are detected but not distinguished from late infection Identifies acute HIV infection HIV-2 reactives can only be differentiated from HIV-1 reactives during confirmation Differentiates and reports HIV-1 p24 antigen and HIV-1 and HIV-2 antibodies BioPlex® 2200 HIV Ag-Ab Assay

5 Improving Efficiency with 5th Generation BioPlex 2200 HIV Ag-Ab Assay
Long specimen stability Up to 4 days at room temperature and 7 days at 2-8°C Consolidates the assay as part of a comprehensive infectious disease menu Lab and workflow consolidation Confidence in test results Three internal quality beads assure consistent and quality results Guides supplemental testing Detects analytes to determine follow-up testing BioPlex® 2200 HIV Ag-Ab Assay

6 BioPlex 2200 HIV Ag-Ab Assay Intended Use / Indications for Use
Pediatric (two years or older) Diagnostic Test HIV-1 Ab, HIV-2 Ab and HIV-1 p24 Ag Pregnant women Solid organ donor Detection and differentiation Not intended for routine use in screening blood or plasma donors Serum or plasma BioPlex® 2200 HIV Ag-Ab Assay

7 Intended Use The BioPlex® 2200 HIV Ag-Ab assay is a multiplex flow immunoassay intended for the simultaneous qualitative detection and differentiation of the individual analytes HIV-1 p24 antigen, HIV-1 (groups M and O) antibodies, and HIV-2 antibodies in human serum or plasma (fresh or frozen K2 EDTA, K3 EDTA, lithium heparin, sodium heparin; fresh citrate). This assay is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2, including acute (primary) HIV-1 infection. The assay may also be used as an aid in the diagnosis of infection with HIV-1 and/or HIV-2 in pediatric subjects as young as two years of age, and pregnant women. The BioPlex® 2200 HIV Ag-Ab assay is also intended for use in testing plasma specimens to screen organ donors when specimens are obtained while the donor’s heart is still beating. The BioPlex® 2200 HIV Ag-Ab assay is not intended for use in screening blood or plasma donors, as the effectiveness of this test for use in the screening of these donors has not been established. However, in urgent situations where traditional licensed blood donor screening tests are unavailable or their use is impractical, this assay can be used as a blood donor screening assay. The BioPlex® 2200 HIV Ag-Ab assay is intended for use with the BioPlex® 2200 system. Warning: FDA has approved this test for use with serum and plasma specimens only. Use of this test kit with specimens other than those specifically approved for use with this test kit may result in inaccurate test results. This test is not intended for use in children younger than 2 years of age. BioPlex® 2200 HIV Ag-Ab Assay

8 Validated Performance Outcomes
Clinical evaluation of BioPlex HIV Ag-Ab, an automated screening method providing discrete detection of HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody* Excellent overall performance in EU clinical studies High analytic sensitivity for HIV-1 p24 Ag. Limit of Detection: 0.637 IU/mL WHO standard or pg/mL ANSA standard High specificity: Hospitalized patient samples % Published in JCM- January 2014, Vol. 52, No. 1, p (Salmona, et al, including Professor Francois Simon * BioPlex® 2200 HIV Ag-Ab Assay

9 Journal of Clinical Microbiology*
EU Clinical Findings Highly sensitive and specific in clinical sample populations Differentiation capability of the 3 important markers Considered a new generation of test This study concludes that the next generation BioPlex HIV Ag-Ab assay performs well in the diagnosis of HIV infection, with excellent sensitivity and specificity Sample Type Differentiation Capability Rate HIV-1: No AHI HIV-1: AHI HIV-2 HIV-1 & HIV-2 100% 90.9% 90.7% Published in JCM- January 2014, Vol. 52, No. 1, p (Salmona, et al, including Professor Francois Simon) * 100% * EU Clinical Performance BioPlex® 2200 HIV Ag-Ab Assay

10 A Diagnostic Test that Fits in the CDC Testing Algorithm
HIV 1/2 Antigen/Antibody Combination Immunoassay Step 1 Diagnostic Test (+) (-) Negative for HIV-1 and HIV-2 Antibodies and p24 Ag HIV 1/2 Antibody Differentiation Assay HIV-1 (+) HIV-2 (-) HIV-1 (-) HIV-2 (+) HIV-1 (+) HIV-2 (+) HIV-1 (-) or indeterminate HIV-2 (-) Step 2 Supplemental and Differentiation HIV-1 antibodies detected HIV-2 antibodies detected HIV antibodies detected HIV-1 NAT HIV-1 NAT (+) Acute HIV-1 Infection HIV-1 NAT (-) Negative for HIV-1 (+) indicates reactive test result (-) indicates non-reactive test result NAT: Nucleic Acid Test BioPlex® 2200 HIV Ag-Ab Assay

11 Key Attributes & Differentiators
Clinical Validation Detects & Differentiates Enhances Efficiency European study published in peer-reviewed journal HIV Ag-Ab Overall Result with HIV-1 p24 Ag, HIV-1 Ab (Groups M & O) and HIV-2 Ab Helps guide supplemental testing High sensitivity Long specimen stability Simultaneously detects and differentiates HIV-1 and HIV-2 infections Lab and workflow consolidation High specificity Enhanced sensitivity for HIV-1 p24 antigen for acute HIV-1 infection detection Comprehensive, quick and confident results Superior reproducibility BioPlex® 2200 HIV Ag-Ab Assay

12 In Conclusion Bio-Rad’s BioPlex HIV Ag-Ab is a fully automated, multiplex flow immunoassay for HIV diagnostic testing Enhanced sensitivity for p24 antigen detection Simultaneously detects and reports an HIV overall result with three individual HIV analyte results Can help guide supplemental testing BioPlex® 2200 HIV Ag-Ab Assay

13 Your Authority in H V Testing
For more information Download Poster BioPlex® 2200 HIV Ag-Ab Assay

14 Thank You

Download ppt "BioPlex 2200 HIV Ag-Ab Assay"

Similar presentations

Chagas Tests: Development and Standardization

Chagas Tests: Development and Standardization
Nick Curry, MD, MPH Infectious Diseases Prevention Section

Nick Curry, MD, MPH Infectious Diseases Prevention Section
High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
Unit 6 Diagnosis & Follow-up of HIV Infection

Unit 6 Diagnosis & Follow-up of HIV Infection
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
Comparative Performance of Dual 3rd Generation Immunoassays as a Potential Laboratory-Based HIV-1/2 Testing Strategy. B. Bennett, S. Fordan, O. David,

Comparative Performance of Dual 3rd Generation Immunoassays as a Potential Laboratory-Based HIV-1/2 Testing Strategy. B. Bennett, S. Fordan, O. David,
Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.

Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.

Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.

Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
1 Development of an Anti-HIV 1+2 Assay for use on a Random Access System B Boyer, S Edwards, JM Glover: Ortho-Clinical Diagnostics, Rochester NY This assay.

1 Development of an Anti-HIV 1+2 Assay for use on a Random Access System B Boyer, S Edwards, JM Glover: Ortho-Clinical Diagnostics, Rochester NY This assay.
Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.

Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.
Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.

Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.
Can Sequentially Reactive EIA’s Replace HIV-1 Western Blot Testing? Robert A. Myers Ph.D.

Can Sequentially Reactive EIA’s Replace HIV-1 Western Blot Testing? Robert A. Myers Ph.D.
6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.

6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.
12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.

12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.
An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.

An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.
Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.

Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.

Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.
Epidemiology of HIV-2 infection in the U.S, 1996-2006 Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,

Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,

Similar presentations

Ads by Google